Evidence map›Paper›PMID 29252087›Full record

ArticleCancer biology & therapy2018

Temozolomide renders murine cancer cells susceptible to oncolytic adenovirus replication and oncolysis.

Rodolfo Garza-Morales, Kavitha Yaddanapudi, Rigoberto Perez-Hernandez, Eric Riedinger, Kelly M McMasters, Haval Shirwan, Esma Yolcu, Roberto Montes de Oca-Luna, Jorge G Gomez-Gutierrez

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Rodolfo Garza-Moralesa The Hiram C. Polk Jr, MD, Department of Surgery , University of Louisville School of Medicine , Louisville , KY , USA.
Kavitha Yaddanapudib James Graham Brown Cancer Center, University of Louisville School of Medicine , Louisville , KY , USA.
Rigoberto Perez-Hernandeza The Hiram C. Polk Jr, MD, Department of Surgery , University of Louisville School of Medicine , Louisville , KY , USA.
Eric Riedingera The Hiram C. Polk Jr, MD, Department of Surgery , University of Louisville School of Medicine , Louisville , KY , USA.
Kelly M McMastersa The Hiram C. Polk Jr, MD, Department of Surgery , University of Louisville School of Medicine , Louisville , KY , USA.
Haval Shirwanc Department of Microbiology and Immunology , Institute for Cellular Therapeutics, University of Louisville , Louisville , KY , USA.
Esma Yolcuc Department of Microbiology and Immunology , Institute for Cellular Therapeutics, University of Louisville , Louisville , KY , USA.
Roberto Montes de Oca-Lunad Department of Histology, School of Medicine , Autonomous University of Nuevo León , Monterrey , N.L. México.
Jorge G Gomez-Gutierreza The Hiram C. Polk Jr, MD, Department of Surgery , University of Louisville School of Medicine , Louisville , KY , USA.ORCID 0000-0003-3610-260X

Funding

University of Louisville Cancer Education ProgramR25CA134283 · NCI · UNIVERSITY OF LOUISVILLE · PI HEIN, DAVID W, KIDD, LA CREIS RENEE · 2011 to 2022
$3.1M
Targeting melanoma hypoxia with lactic acid bacterium L. lactisR21CA210202 · NCI · UNIVERSITY OF LOUISVILLE · PI GOMEZ-GUTIERREZ, JORGE G · 2017 to 2018
$368k
NCI NIH HHS R21 CA210202NCI NIH HHS R25 CA134283
6 · The paper itself

Abstract

The preclinical evaluation of oncolytic adenoviruses (OAds) has been limited to cancer xenograft mouse models because OAds replicate poorly in murine cancer cells. The alkylating agent temozolomide (TMZ) has been shown to enhance oncolytic virotherapy in human cancer cells; therefore, we investigated whether TMZ could increase OAd replication and oncolysis in murine cancer cells. To test our hypothesis, three murine cancer cells were infected with OAd (E1b-deleted) alone or in combination with TMZ. TMZ increased OAd-mediated oncolysis in all three murine cancer cells tested. This increased oncolysis was, at least in part, due to productive virus replication, apoptosis, and autophagy induction. Most importantly, murine lung non-cancerous cells were not affected by OAd+TMZ. Moreover, TMZ increased Ad transduction efficiency. However, TMZ did not increase coxsackievirus and adenovirus receptor; therefore, other mechanism could be implicated on the transduction efficiency. These results showed, for the first time, that TMZ could render murine tumor cells more susceptible to oncolytic virotherapy. The proposed combination of OAds with TMZ presents an attractive approach towards the evaluation of OAd potency and safety in syngeneic mouse models using these murine cancer cell-lines in vivo.

Indexed as

AdenoviridaeAnimalsAntineoplastic Agents, AlkylatingApoptosisAutophagyCell Line, TumorCombined Modality TherapyDrug Evaluation, PreclinicalGenetic VectorsMiceNeoplasmsOncolytic VirotherapyOncolytic VirusesReceptors, VirusTemozolomideTransduction, Geneticadenovirus receptorAntineoplastic Agents, AlkylatingReceptors, VirusTemozolomideAdenoviruscancermurineoncolyticvirotherapy

Identifiers

PMID29252087
PMCPMC5836815

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.